Encainide

Chemical compound
  • C01BC08 (WHO)
Legal statusLegal status
  • Withdrawn
Identifiers
  • 4-Methoxy-N-[2-(1-methyl-2-piperidin-1-ylethyl)phenyl]benzamide
CAS Number
  • 66778-36-7 checkY
PubChem CID
  • 48041
DrugBank
  • DB01228 checkY
ChemSpider
  • 43697 checkY
UNII
  • SY3J0147NB
KEGG
  • D07894 checkY
ChEBI
  • CHEBI:4788 checkY
ChEMBL
  • ChEMBL315838 ☒N
CompTox Dashboard (EPA)
  • DTXSID0022983 Edit this at Wikidata
Chemical and physical dataFormulaC22H28N2O2Molar mass352.478 g·mol−13D model (JSmol)
  • Interactive image
  • COc1ccc(C(=O)Nc2ccccc2CCC2CCCCN2C)cc1
InChI
  • InChI=1S/C22H28N2O2/c1-24-16-6-5-8-19(24)13-10-17-7-3-4-9-21(17)23-22(25)18-11-14-20(26-2)15-12-18/h3-4,7,9,11-12,14-15,19H,5-6,8,10,13,16H2,1-2H3,(H,23,25) checkY
  • Key:PJWPNDMDCLXCOM-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Encainide (trade name Enkaid) is a class Ic antiarrhythmic agent. It is no longer used because of its frequent proarrhythmic side effects.[1]

Synthesis

Synthesis:[2]<

See also

References

  1. ^ Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al. (March 1991). "Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial". The New England Journal of Medicine. 324 (12): 781–8. doi:10.1056/NEJM199103213241201. PMID 1900101.
  2. ^ Dykstra SJ, Minielli JL, Lawson JE, Ferguson HC, Dungan KW (September 1973). "Lysergic acid and quinidine analogs. 2-(o-Acylaminophenethyl)piperidines". Journal of Medicinal Chemistry. 16 (9): 1015–20. doi:10.1021/jm00267a012. PMID 4745503.
  • v
  • t
  • e
Calcium
VDCCsTooltip Voltage-dependent calcium channels
Blockers
Activators
Potassium
VGKCsTooltip Voltage-gated potassium channels
Blockers
Activators
IRKsTooltip Inwardly rectifying potassium channel
Blockers
Activators
  • GIRKTooltip G protein-coupled inwardly rectifying potassium channel-specific: ML-297 (VU0456810)
KCaTooltip Calcium-activated potassium channel
Blockers
  • BKCa-specific: Ethanol (alcohol)
  • GAL-021
Activators
K2PsTooltip Tandem pore domain potassium channel
Blockers
Activators
Sodium
VGSCsTooltip Voltage-gated sodium channels
Blockers
Activators
ENaCTooltip Epithelial sodium channel
Blockers
Activators
  • Solnatide
ASICsTooltip Acid-sensing ion channel
Blockers
Chloride
CaCCsTooltip Calcium-activated chloride channel
Blockers
Activators
CFTRTooltip Cystic fibrosis transmembrane conductance regulator
Blockers
Activators
Unsorted
Blockers
Others
TRPsTooltip Transient receptor potential channels
  • See here instead.
LGICsTooltip Ligand gated ion channels
  • See here instead.
See also: Receptor/signaling modulators • Transient receptor potential channel modulators
  • v
  • t
  • e
Channel blockers
class I
(Na+ channel blockers)
class Ia (Phase 0→ and Phase 3→)
class Ib (Phase 3←)
class Ic (Phase 0→)
class III
(Phase 3→, K+ channel blockers)
class IV
(Phase 4→, Ca2+ channel blockers)
Receptor agonists
and antagonists
class II
(Phase 4→, β blockers)
A1 agonist
M2
α receptors
Ion transporters
Na+/ K+-ATPase
Stub icon

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e